Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Researchers achieve a significant milestone in the management of anemia in chronic lymphocytic leukemia.

2.

Researchers can now forecast how prostate cancer bone metastases will react to radium-223 treatment.

3.

The Kansas Cancer Center awarded two Indian American doctors professorships.

4.

Frontline EGFR/VEGF Inhibition Slows Advanced EGFR-Positive Lung Cancer

5.

Increased Data Support Active Monitoring for Low-Risk Prostate Cancer.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot